ACADIA Pharmaceuticals

Traded on the St. Petersburg Stock Exchange
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. Nuplazid, a drug developed by Acadia to treat hallucinations and delusions associated with psychosis in Parkinson's disease.
ACADIA Pharmaceuticals stock price chart
-6%
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

ACADIA Pharmaceuticals balance sheet

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

ACADIA Pharmaceuticals cash flows

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

ACADIA Pharmaceuticals multipliers

Report period2016 2017 2018 2019 2020 2021
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

ACADIA Pharmaceuticals profitability

Report period2016 2017 2018 2019 2020 2021
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
ACADIA Pharmaceuticals assets
ACADIA Pharmaceuticals cash flows

ACADIA Pharmaceuticals shares

TickerNameTypeNominal valueISINPrice
ACAD:USACADIA Pharmaceuticals, Inc.Common share-US0042251084$16.36
ACAD-RM:RMAcadia PharmaceuticalsCommon share$0.0001US0042251084RUB 1,300
ACADIA Pharmaceuticals news
05.05.2022
ACADIA Pharmaceuticals' GAAP loss for the 3 months of 2022 was $113.056 million, up 70.1% from $66.448 million in the previous year. Revenue increased 8.4% to $115.468 million from $106.554 million a year earlier.
01.03.2022
ACADIA Pharmaceuticals' GAAP loss for 2021 was $167.87 million, down 40.4% from $281.584 million in the previous year. Revenue increased 9.6% to $484.145 million from $441.755 million a year earlier.
09.11.2021
ACADIA Pharmaceuticals reported a GAAP loss of $124.776 million for 9M 2021, down 41.9% from $214.824 million in the previous year. Revenue increased 10.2% to $353.387 million from $320.748 million a year earlier.
04.08.2021
ACADIA Pharmaceuticals reported a GAAP loss of $110.319 million for the six months of 2021, down 15.2% from $130.164 million in the previous year. Revenue increased 10.8% to $221.775 million from $200.171 million a year earlier.
General information
Company nameACADIA Pharmaceuticals
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address3611 VALLEY CENTRE DRIVE SUITE 300 SAN DIEGO CA 92130 858-558-2871
Mailing address3611 VALLEY CENTRE DRIVE SUITE 300 SAN DIEGO CA 92130
Websitewww.acadia-pharm.com
Information disclosurewww.sec.gov